Study guide
Surface healing, amnion and cenegermin
European Board of Ophthalmology Diploma EBOD
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: EBOD Examination, Applications and Regulations
EBOD Format, Scoring and Revision Planning Eligibility, Applications and the Diploma Online Rules, Technical Preparation and Appeals
2 Chapter 2: Physical Optics, Photometry and Lenses
Light, refraction and total internal reflection Photometry, contrast, colour and adaptation Prisms, decentration and vector combination Vergence, astigmatic lenses and Sturm’s conoid
3 Chapter 3: Instrument Optics, Aberrations and Laser Physics
Cross-cylinder and diagnostic instrument optics Aberrations, duochrome and wavefront analysis Diffraction, polarization, lasers and OCT
4 Chapter 4: Refraction, Accommodation and Spectacle Prescribing
Objective and cycloplegic refraction Subjective refraction and binocular balance Accommodation, presbyopia and vertex distance Spectacle Materials, Measurement and Progressive Lenses
5 Chapter 5: Contact Lenses and Low-Vision Rehabilitation
Contact-lens optics, materials and tear lenses Contact-lens fit and complications Low-vision assessment and magnification Low-vision aids, calculations and ergonomics
6 Chapter 6: Extraocular Anatomy and Motor Physiology
Extraocular muscle anatomy and innervation Eye axes, kinematics and muscle actions Motor laws and orbital pulleys
7 Chapter 7: Binocular Vision and Amblyopia
Binocular vision, stereopsis and the horopter Suppression, correspondence and microtropia Sensory tests and amblyopia treatment
8 Chapter 8: Childhood Assessment and Strabismus Testing
Visual Development, Childhood Testing and Developmental Delay History, corneal reflexes and cover tests Motility patterns, three-step testing and Hess charts
9 Chapter 9: Esotropia, Exotropia and Vertical Deviations
Infantile and accommodative esotropia Exotropia classification and management Vertical Deviations, A–V Patterns and Skew
10 Chapter 10: Dysinnervation, Nystagmus and Muscle Surgery
Duane syndrome, Brown syndrome and restriction Nystagmus patterns and investigation Nystagmus and muscle surgery principles
11 Chapter 11: ROP and Paediatric Ocular Disease
Retinopathy of Prematurity: Screening, Classification and Follow-up Childhood Cataract, Leukocoria and Congenital Glaucoma Childhood Systemic Disease, Infection and Safeguarding
12 Chapter 12: Ocular Surface Anatomy and Infection
Corneal, Conjunctival and Scleral Structure: Examination and Sampling Bacterial keratitis, sampling and treatment Fungal, amoebic and herpetic keratitis Infectious, chlamydial and neonatal conjunctivitis
13 Chapter 13: Allergy, Cicatrisation and Surface Inflammation
Allergic eye disease, trachoma and phlyctenules Cicatrising Conjunctivitis: Mucous Membrane Pemphigoid and SJS/TEN Dry eye, blepharitis and meibomian dysfunction PUK, interstitial keratitis and scleritis
14 Chapter 14: Anterior Segment Dysgenesis and Corneal Dystrophies
Anterior Segment Dysgenesis, Aniridia and Congenital Corneal Opacity IC3D and epithelial or Bowman-layer dystrophies Stromal corneal dystrophies Endothelial corneal dystrophies
15 Chapter 15: Corneal Degeneration, Ectasia and Epithelial Failure
Corneal Degenerations, Pterygium, Band Keratopathy and Dellen Keratoconus and clinical ectasia signs Ectasia imaging, cross-linking and rehabilitation Recurrent Erosion, Neurotrophic Keratopathy and Vitamin A Deficiency
16 Chapter 16: Surface Reconstruction and Keratoplasty
Limbal Stem-Cell Failure, Tarsorrhaphy and Phototherapeutic Keratectomy PK, DALK and endothelial keratoplasty Corneal graft immunity and rejection recognition Graft rejection treatment and postoperative problems
17 Chapter 17: Lens Development, Cataract Assessment and Biometry
Lens Development, Congenital Shape and Ectopia Lentis Lens anatomy and age-related cataract phenotypes Cataract grading, secondary causes and childhood disease Optical and ultrasound biometry
18 Chapter 18: IOL Planning and Phacoemulsification
Keratometry and IOL power formulae Post-refractive biometry, toric alignment and IOL design Phaco fluidics and ultrasound delivery Wounds, OVDs and nucleus techniques
19 Chapter 19: Cataract Anaesthesia and Surgical Complications
Cataract Anaesthesia, Alternative Extraction and Combined Procedures IFIS, capsule rupture and compromised support Postoperative inflammation, haemorrhage and PCO
20 Chapter 20: Corneal and Intraocular Refractive Surgery
Excimer ablation, PRK and LASIK SMILE, surgical selection and complications Phakic IOLs and refractive lens exchange
21 Chapter 21: Presbyopia Procedures and Surface Therapeutics
Presbyopia Surgery, Monovision and Historical Refractive Procedures Surface antimicrobial and anti-inflammatory pharmacology Surface healing, amnion and cenegermin
22 Chapter 22: Aqueous Dynamics, Tonometry and Gonioscopy
Ciliary body and aqueous secretion Outflow and the Goldmann pressure model Tonometry, corneal thickness and biomechanics Gonioscopy optics, landmarks and indentation
23 Chapter 23: Angle, Disc and Visual-Field Assessment
Angle grading and anterior-segment imaging Optic-disc examination and documentation OCT and automated perimetry
24 Chapter 24: Glaucoma Progression, Suspects and Secondary Mechanisms
Field reliability and progression Ocular hypertension, suspects and juvenile glaucoma Lens-related glaucoma, aqueous misdirection and venous pressure
25 Chapter 25: POAG, Angle Closure and Pigmentary Disease
POAG, target pressure and normal-tension disease Angle-closure classification and mechanisms Acute angle closure, iridotomy and lens extraction Pseudoexfoliation and pigmentary glaucoma
26 Chapter 26: Glaucoma Medical, Laser and Surgical Treatment
Neovascular, uveitic and steroid-response glaucoma Glaucoma medicines, SLT and MIGS Trabeculectomy and drainage implants Nonpenetrating surgery, cyclodestruction and postoperative lasers
27 Chapter 27: Retinal Imaging, Diabetes and Vascular Occlusion
Retinal anatomy, examination and multimodal imaging Diabetic microangiopathy and NPDR classification PDR, macular oedema and diabetic trials Retinal vein and artery occlusions
28 Chapter 28: Uncommon Vascular Disease and Myopic Maculopathy
Macroaneurysm, sickle retinopathy and retinal periphlebitis Coats disease and leukocoria assessment MacTel and radiation retinopathy Myopic maculopathy and presumed ocular histoplasmosis
29 Chapter 29: Inherited Retina and Electrophysiology
Retinitis pigmentosa and inherited degeneration Stargardt, Best disease and retinal electrophysiology Cone disorders, stationary night blindness and syndromic retina
30 Chapter 30: AMD, Geographic Atrophy and Pachychoroid
AMD biology and clinical staging Drusen, geographic atrophy and neovascular phenotypes Neovascular AMD trials and treatment CSCR and the pachychoroid spectrum
31 Chapter 31: Retinal Breaks and Detachment Repair
PVD, peripheral degenerations and retinal breaks RRD localization and retinoschisis Detachment mechanisms, pneumatic retinopexy and scleral buckling
32 Chapter 32: Vitrectomy, Macular Surgery and Retinal Trauma
Vitrectomy and intraocular tamponades ERM, macular holes and PVR Retinal trauma, optic-disc pits and choroidal detachment
33 Chapter 33: Uveitis Classification and Non-Infectious Inflammation
SUN classification, grading and uveitis work-up Anterior and intermediate uveitis patterns HLA-B27, sarcoidosis, Behçet disease and VKH Posterior inflammatory patterns and immunomodulation
34 Chapter 34: Infectious Uveitis and Endophthalmitis
Toxoplasmosis and herpetic necrotizing retinitis Ocular syphilis and tuberculosis Immunosuppressed retinitis, toxocariasis and neuroretinitis Endophthalmitis diagnosis and treatment
35 Chapter 35: Optic Neuritis and Ischaemic Optic Neuropathy
Typical optic neuritis and ONTT NMOSD and MOGAD Arteritic optic neuropathy and GCA NAION and ischaemic neuropathy comparison
36 Chapter 36: Papilloedema, IIH and Afferent Localisation
Papilloedema recognition and Frisén grading IIH diagnosis and vision protection Disc drusen and pseudopapilloedema Afferent pathways and chiasmal localization
37 Chapter 37: Congenital, Inherited and Cortical Neuro-Ophthalmology
Cortical vision and higher visual syndromes Neuro-ophthalmic testing and congenital optic discs Inherited, compressive, infiltrative and nutritional optic neuropathies Transient visual loss, headache and neurological emergencies
38 Chapter 38: Central Motor Control and Cranial Nerve Palsies
Central ocular motor control and supranuclear disorders Third- and fourth-nerve palsies Sixth nerve, pontine gaze and cavernous sinus
39 Chapter 39: Myasthenia and Ocular Myopathy
Myasthenic ocular weakness Myasthenia testing and treatment Myopathy, CPEO and Kearns–Sayre syndrome
40 Chapter 40: Pupillary Pathways and Anisocoria
Pupillary pathways and afferent defects Horner syndrome and tonic pupil Light–near dissociation and pupil differentials
41 Chapter 41: Orbit, Thyroid Eye Disease and Ptosis Assessment
Orbital anatomy and thyroid eye disease Orbital infection and idiopathic inflammation Orbital masses, approaches and eye-removal procedures Lid anatomy and ptosis evaluation
42 Chapter 42: Lid Repair and Lacrimal Drainage
Ptosis repair, malposition and eyelid tumours Lash disorders, facial palsy and lid reconstruction Lacrimal drainage and epiphora testing Nasolacrimal obstruction, infection and DCR
43 Chapter 43: Lacrimal Gland Disease, Pathology and Intraocular Tumours
Lacrimal gland inflammation and tumours Ocular histology, specimen handling and special stains Immunophenotyping, molecular pathology and tumour genetics Uveal melanoma and retinoblastoma
44 Chapter 44: Lymphoma, Surface Tumours and Paraneoplastic Disease
Vitreoretinal lymphoma Surface tumours, uveal metastases and benign mimics Paraneoplastic retinopathy, treatment effects and counselling
45 Chapter 45: Ocular Trauma and Vascular Systemic Disease
Trauma terminology and prognostic scoring Chemical injury and surface preservation Open-globe emergency management Vascular, endocrine, pregnancy and renal eye disease
46 Chapter 46: Multisystem Disease and Ophthalmic Pharmacology
Immune, metabolic and multisystem ocular clues Phakomatoses and syndrome-specific surveillance Connective-tissue and metabolic ocular disease Drug delivery and systemic glaucoma effects
47 Chapter 47: Medication Toxicity, Professional Practice and Clinical Stations
Retinal and optic medication toxicity Prevention, consent and professional practice Directed clinical answers and station rehearsal
Surface healing, amnion and cenegermin
Key Takeaways Explain This Topic AI
Persistent epithelial defects require assessment of sensation, tears, lid mechanics, limbal function and infection.
Amniotic membrane can support healing but cannot correct every ongoing mechanical or inflammatory driver.
European cenegermin treatment uses six daily doses for eight weeks in the indicated adult neurotrophic disease setting.
Last updated: October 2026
- 4. Corneal Wound Healing & Regenerative Therapies
- Autologous Serum Tears (AST) & Platelet-Rich Plasma (PRP)
Conventional artificial lubricants lack the biological, epitheliotropic, and neurotrophic factors present in human tears. Autologous Serum Tears (AST) are prepared from the patient's own peripheral blood (centrifuged after clotting, separated, and diluted to 20 % 20\% 20% , 50 % 50\% 50% , or 100 % 100\% 100% in sterile balanced salt solution without preservatives):
Biochemical Composition : Supplies critical factors essential for epithelial proliferation and wound healing:
Epidermal Growth Factor (EGF) : Accelerates epithelial cell migration and mitosis.
Transforming Growth Factor- β \beta β (TGF- β \beta β ) : Regulates cell differentiation and stromal repair.
Fibronectin : Provides an extracellular matrix scaffold promoting epithelial adhesion.
Vitamin A & Substance P : Prevent squamous metaplasia and promote corneal nerve maintenance.
Lysozyme & serum immunoglobulins (predominantly IgG) : Confer antimicrobial protection.
Indications : Persistent epithelial defects (PED), severe dry eye disease (Sjögren syndrome), neurotrophic keratitis, ocular graft-versus-host disease (GvHD), and chemical burns.
Platelet-Rich Plasma (PRP) : Centrifuged from anti-coagulated whole blood to concentrate platelets 3- to 5-fold, delivering even higher concentrations of PDGF, VEGF, and FGF.
Amniotic Membrane Transplantation (AMT)
The human amniotic membrane—the innermost layer of the fetal placenta—possesses unique biological properties that promote ocular surface reconstruction:
Histological Structure : An avascular stroma, a thick collagenous basement membrane (rich in laminin-5, type IV, V, and VII collagens, and fibronectin), and an epithelial layer whose cell viability and biological properties depend on processing.
Biological Properties & Molecular Mechanisms
Anti-Scarring / Anti-Fibrotic : Upregulates basic fibroblast growth factor (bFGF) while suppressing TGF- β 1 \beta 1 β 1 , TGF- β 2 \beta 2 β 2 , and TGF- β \beta β receptor II expression in stromal keratocytes, inhibiting transformation into myofibroblasts and reducing corneal haze.
Anti-Inflammatory : Contains Heavy Chain-Hyaluronan / Pentraxin 3 (HC-HA/PTX3) complexes that entrap inflammatory cells, induce rapid apoptosis of activated neutrophils, and downregulate pro-inflammatory cytokines (IL-1 α \alpha α , IL-1 β \beta β , IL-6, TNF- α \alpha α ).
Anti-Angiogenic : Synthesises tissue inhibitors of metalloproteinases ( TIMP-1, TIMP-2, TIMP-3, TIMP-4 ), endostatin, and thrombospondin-1, potently suppressing pathological corneal neovascularisation.
Scaffold for Epithelial Migration : Serves as a surrogate basement membrane, providing adhesion sites for migrating limbal epithelial stem cells.
Clinical Preparation Modalities & Surgical Techniques
Cryopreserved Amniotic Membrane : Stored at − 80 ∘ C -80^\circ\text{C} − 8 0 ∘ C in Dulbecco's Modified Eagle Medium (DMEM) with glycerol/DMSO. Commercial sutureless devices ( Prokera ) mount cryopreserved amniotic membrane between two polycarbonate rings, inserted directly into the fornices under topical anaesthesia.
Dehydrated / Lyophilised Amniotic Membrane : Ambient-temperature stable, vacuum-dried sheets ( AmbioDisk , Omnigen ) rehydrated intraoperatively with saline and covered by a bandage contact lens.
Surgical Techniques :
Inlay ("Graft") Technique : Sized to match the stromal ulcer bed, placed epithelial/basement membrane side facing up (stromal side down) and sutured with 10-0 nylon or secured with fibrin glue. Host epithelial cells migrate over the membrane, which incorporates permanently into the corneal stroma.
Overlay ("Patch") Technique : Placed across the entire cornea and limbus, epithelial side facing down , functioning as a biological bandage lens to protect underlying tissue. The patch sheds or is removed after 1 to 2 weeks.
5. Neurotrophic Keratitis (NK) & Cenegermin
Neurotrophic keratitis is a degenerative corneal disease triggered by impairment of corneal sensory innervation from the ophthalmic division of the trigeminal nerve ( V 1 V_1 V 1 ) . Common etiologies include Herpes Simplex Keratitis, Herpes Zoster Ophthalmicus, acoustic neuroma (vestibular schwannoma) resection, diabetic neuropathy, and chronic topical drug toxicity (preservatives, beta-blockers, NSAIDs).
Pathophysiological Cascade
Sensory trigeminal denervation abolishes the protective blink reflex and sensory-evoked tearing. Crucially, denervation depletes essential trophic sensory neuropeptides—predominantly Substance P , Calcitonin Gene-Related Peptide (CGRP) , and acetylcholine . Without these trophic factors, corneal epithelial cellular mitosis is arrested, microvilli vanish, cell-matrix adhesion fails, and spontaneous breakdown occurs without pain.
Mackie Staging System of Neurotrophic Keratitis
Mackie Stage Clinical Biomicroscopic Features Pathophysiological Status Stepwise Therapeutic Ladder
Stage 1 (Mild) Epithelial irregularity, superficial punctate keratopathy (PEK), patchy rose bengal staining, tear film instability, perilimbal ciliary flush Cellular metabolic dysfunction, loss of epithelial microvilli Discontinue toxic/preserved drops; frequent preservative-free lubricants; therapeutic soft contact lens
Stage 2 (Moderate) Persistent Epithelial Defect (PED) with characteristic smooth, rolled, thickened, grey-white borders ; underlying stromal oedema; sterile AC flare Complete failure of epithelial migration and basement membrane re-anchoring Cenegermin (rhNGF 20 µg/mL) ; Autologous serum tears ( 20 – 50 % 20–50\% 20–50% ); Amniotic membrane (Prokera/overlay); Botulinum ptosis or tarsorrhaphy
Stage 3 (Severe) Deep stromal ulceration , stromal melting ( keratolysis ), descemetocele, risk of spontaneous perforation Progressive stromal enzymatic lysis by unrestrained collagenases Cenegermin; Multilayered AMT; Cyanoacrylate tissue glue with BCL; Tectonic penetrating or lamellar keratoplasty
Cenegermin (Recombinant Human Nerve Growth Factor)
Until recently, neurotrophic keratitis management was purely supportive. The approval of Cenegermin 20 μ g \mu\text{g} μ g /mL (Oxervate) introduced the first targeted neuro-regenerative pharmacotherapy for moderate and severe neurotrophic keratitis (Mackie Stages 2 and 3).
Molecular Biology : Cenegermin is a recombinant human nerve growth factor ( rhNGF ) produced in Escherichia coli , identical in amino acid sequence to endogenous human NGF.
Receptor Targets : Binds with high affinity to the Tropomyosin receptor kinase A (TrkA) receptor and with low affinity to the p75 neurotrophin receptor (p75NTR) expressed on corneal epithelial cells, stromal keratocytes, and sub-basal sensory nerve fibers.
Downstream Cellular Effects :
Directly stimulates corneal epithelial cell proliferation, migration, and differentiation.
Upregulates synthesis of adhesion molecules, promoting rapid basement membrane re-anchoring.
Promotes survival, sprouting, and elongation of damaged trigeminal sensory nerve endings, supporting corneal epithelial healing; sensory recovery is variable.
EU indication : Oxervate is indicated for moderate or severe neurotrophic keratitis in adults (stages 2 and 3). Epithelial healing improves in trials but is not assured in every patient, and recurrence or persisting sensory loss may need further treatment.
Administration : One drop six times daily at two-hour intervals for eight weeks, using the supplied daily-vial and pipette system.
Storage : Pharmacy frozen storage is different from patient storage. Patients refrigerate the weekly carton at 2–8°C according to the EU leaflet, and follow its daily-vial handling and discard instructions; do not instruct patients to freeze the medicine.
See the EMA product information . Check the live local leaflet because handling instructions may differ between jurisdictions.
Surgical Interventions: Tarsorrhaphy & Corneal Neurotisation
Tarsorrhaphy : Surgical or chemical (botulinum toxin A injection into the levator palpebrae superioris muscle) closure of the eyelid aperture protects the denervated cornea from mechanical micro-trauma and evaporative desiccation, facilitating epithelial closure.
Corneal Neurotisation : For irreversible, complete trigeminal sensory loss, surgical neurotisation restores corneal innervation by rerouting a functional sensory donor nerve—such as the contralateral or ipsilateral supraorbital , supratrochlear , or great auricular nerve —directly or via an interpositional sural nerve graft to the perilimbal subconjunctival space. Over 6 to 12 months, axon sprouting restores corneal sensation, trophic support, and epithelial durability.